Implicit|09|75||||351|2||because|for example|Contingency.Cause.Reason||Expansion.Conjunction||Wr|Comm|Null|Null||||199..349|1|The National Institutes of Health policy would require researchers to cut financial ties with health-care businesses -- or lose their government money|Inh|Null|Null|Null||||351..371;389..482|2,0;2,1;2,3,1;2,4|Among other concerns researchers with business ties are more likely to falsify findings in order to tout new drugs|Ot|Comm|Null|Null|373..388|2,1;2,2;2,3,0;2,4|the agency says||||||
Implicit|09|75||||484|3||so||Contingency.Cause.Result||||Wr|Comm|Null|Null||||389..482|2,3,1|researchers with business ties are more likely to falsify findings in order to tout new drugs|Ot|Comm|Null|Null|351..388|2,0;2,1;2,2;2,3,0;2,4|Among other concerns, the agency says|484..597|3|As ties between academia and venture capital have blossomed in recent years, governmental fear of abuse has risen|Inh|Null|Null|Null|||||||||
Explicit|09|75|484..486|3,0,0|As|||as|||Temporal.Synchrony|Contingency.Cause.Reason|||Wr|Comm|Null|Null||||561..597|3,1;3,2;3,3;3,4|governmental fear of abuse has risen|Inh|Null|Null|Null||||487..559|3,0,1|ties between academia and venture capital have blossomed in recent years|Inh|Null|Null|Null|||||||||
Explicit|09|75|601..604|4,0,0|But|||but|||Comparison||||Wr|Comm|Null|Null||||199..315|1,0;1,1,0;1,1,1,0;1,1,1,1,0;1,1,1,1,1,0;1,1,1,1,1,1,0;1,1,1,1,1,1,1;1,2|The National Institutes of Health policy would require researchers to cut financial ties with health-care businesses|Inh|Null|Null|Null||||605..671|4,0,1;4,0,2|the guidelines could "make it impossible to commercialize research|Ot|Comm|Null|Null|674..784|4,1;4,2;4,3;4,4;4,5|says Kenneth Smith, associate provost and vice president for research at Massachusetts Institute of Technology|319..349|1,1,1,1,1,1,2;1,1,1,1,1,1,3|or lose their government money|||
Implicit|09|75||||889|6||and||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||788..887|5|The NIH is asking grant recipients and others for comments on the proposed guidelines until Dec. 15|Inh|Null|Null|Null||||889..944|6|After that, it will make a final decision on the policy|Inh|Null|Null|Null|||||||||
Implicit|09|75||||1139|8||specifically||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||948..1058|7,0|The guidelines could foil future arrangements similar to the deal behind Lithox Inc., a Salem, Mass., start-up|Ot|Comm|Null|Null|1060..1137|7,1;7,2;7,3;7,4|says Robert Daly, a managing partner of TA Associates, a venture-capital firm|1139..1309;1313..1653|8;9;10,0|With $2.3 million, he and other investors launched Lithox last year to market a gallstone cure being developed by researchers of the University of California at San Diego The researchers, who are being financed by the Lithox funds, will receive a royalty, or percentage of sales, if their research yields a commercial product.But because the University of California, like many other universities, shares its royalties with researchers, it may disqualify itself from federal funds under the proposed guidelines|Ot|Comm|Null|Null|1655..1668|10,1;10,2;10,3|Mr. Daly says||||||
Explicit|09|75|1422..1424|9,1,1,2,0|if|||if|||Contingency.Condition.Hypothetical||||Wr|Comm|Null|Null||||1313..1328;1374..1420|9,0,0;9,0,1;9,0,3;9,1,0;9,1,1,0;9,1,1,1|The researchers will receive a royalty, or percentage of sales|Inh|Null|Null|Null||||1425..1467|9,1,1,2,1|their research yields a commercial product|Inh|Null|Null|Null||||1330..1372|9,0,2|who are being financed by the Lithox funds|||
Explicit|09|75|1469..1472|10,0,0|But|||but|||Comparison||||Ot|Comm|Null|Null|1655..1668|10,1;10,2;10,3|Mr. Daly says|1313..1467|9|The researchers, who are being financed by the Lithox funds, will receive a royalty, or percentage of sales, if their research yields a commercial product|Inh|Null|Null|Null||||1473..1653|10,0,1;10,0,2;10,0,3;10,0,4;10,0,5|because the University of California, like many other universities, shares its royalties with researchers, it may disqualify itself from federal funds under the proposed guidelines|Inh|Null|Null|Null|||||||||
Explicit|09|75|1473..1480|10,0,1,0|because|||because|||Contingency.Cause.Reason||||Ot|Comm|Null|Null|1655..1668|10,1;10,2;10,3|Mr. Daly says|1469..1472;1580..1653|10,0,0;10,0,2;10,0,3;10,0,4;10,0,5|But it may disqualify itself from federal funds under the proposed guidelines|Inh|Null|Null|Null||||1481..1578|10,0,1,1|the University of California, like many other universities, shares its royalties with researchers|Inh|Null|Null|Null|||||||||
Explicit|09|75|1768..1780|12,0|For instance|||for instance|||Expansion.Instantiation||||Wr|Comm|Null|Null||||1672..1766|11|The high-tech industry is full of the kind of arrangement that the new guidelines would affect|Inh|Null|Null|Null||||1782..1952|12,1;12,2;12,3;12,4;12,5|Commonwealth BioVentures Inc., a venture-capital concern, last month invested $600,000 to launch Amira Inc., a Worcester, Mass., concern that will produce pharmaceuticals|Inh|Null|Null|Null|||||||||
Implicit|09|75||||1954|13||earlier||Temporal.Asynchronous.Succession||||Wr|Comm|Null|Null||||1768..1952|12|For instance, Commonwealth BioVentures Inc., a venture-capital concern, last month invested $600,000 to launch Amira Inc., a Worcester, Mass., concern that will produce pharmaceuticals|Inh|Null|Null|Null||||1954..2078|13|Scientists Rima Kaddurah-Daouk and Paul Schimmel conducted the initial research at the Massachusetts Institute of Technology|Inh|Null|Null|Null|||||||||
Implicit|09|75||||2080|14||and||Expansion.Conjunction||||Wr|Comm|Null|Null||||1954..2078|13|Scientists Rima Kaddurah-Daouk and Paul Schimmel conducted the initial research at the Massachusetts Institute of Technology|Inh|Null|Null|Null||||2080..2240|14|While Ms. Kaddurah-Daouk left MIT to head Amira, Prof.Schimmel will continue to work at MIT, serve on Amira's board and own a small equity stake in the company|Inh|Null|Null|Null|||||||||
Explicit|09|75|2080..2085|14,0,0|While|||while|||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||2129..2240|14,1;14,2;14,3;14,4|Prof.Schimmel will continue to work at MIT, serve on Amira's board and own a small equity stake in the company|Inh|Null|Null|Null||||2086..2127|14,0,1|Ms. Kaddurah-Daouk left MIT to head Amira|Inh|Null|Null|Null|||||||||
Implicit|09|75||||2378|16||because||Contingency.Cause.Reason||||Ot|Comm|Null|Null|2510..2550|16,1;16,2;16,3;16,4;16,5|says Gloria W. Doubleday of Commonwealth|2244..2376|15|The Amira transaction is typical of the way venture-capital firms are approaching the task of commercializing biotechnology research|Inh|Null|Null|Null||||2378..2507|16,0|While universities develop the basic research, "venture capitalists are the ones best positioned to finance its commercialization|Inh|Null|Null|Null|||||||||
Explicit|09|75|2378..2383|16,0,0,0|While|||while|||Comparison.Contrast.Juxtaposition||||Ot|Comm|Null|Null|2510..2550|16,1;16,2;16,3;16,4;16,5|says Gloria W. Doubleday of Commonwealth|2426..2507|16,0,1;16,0,2;16,0,3;16,0,4|venture capitalists are the ones best positioned to finance its commercialization|Inh|Null|Null|Null||||2384..2423|16,0,0,1|universities develop the basic research|Inh|Null|Null|Null|||||||||
Implicit|09|75||||2553|17||indeed||Expansion.Conjunction||||Ot|Comm|Null|Null|2510..2550|16,1;16,2;16,3;16,4;16,5|says Gloria W. Doubleday of Commonwealth|2378..2507|16,0|While universities develop the basic research, "venture capitalists are the ones best positioned to finance its commercialization|Inh|Null|Null|Null||||2553..2638|17|This is the best way to transfer technology straight off the campuses of universities|Inh|Null|Null|Null|||||||||
Explicit|09|75|2643..2646|18,0,0|But|||but|||Comparison.Contrast||||Wr|Comm|Null|Null||||2129..2240|14,1;14,2;14,3;14,4|Prof.Schimmel will continue to work at MIT, serve on Amira's board and own a small equity stake in the company|Inh|Null|Null|Null||||2647..2759|18,0,1;18,0,2;18,0,3|the new guidelines could prevent scientists like Prof.Schimmel from being involved with start-ups such as Amira|Ot|Comm|Null|Null|2761..2790|18,1;18,2;18,3|venture capitalists point out||||||
Explicit|09|75|2792..2795|19,0,0|And|||and|||Expansion.Conjunction||||Wr|Comm|Null|Null||||2643..2759|18,0|But the new guidelines could prevent scientists like Prof.Schimmel from being involved with start-ups such as Amira|Ot|Comm|Null|Null|2761..2790|18,1;18,2;18,3|venture capitalists point out|2796..2893|19,0,1;19,0,2;19,0,3;19,0,4;19,0,5|if that happens, the entire process of transferring technology to the marketplace could be harmed|Ot|Comm|Null|Null|2895..2903|19,1;19,2;19,3|they say||||||
Explicit|09|75|2796..2798|19,0,1,0|if|||if|||Contingency.Condition.Hypothetical||||Ot|Comm|Null|Null|2895..2903|19,1;19,2;19,3|they say|2792..2795;2813..2893|19,0,0;19,0,2;19,0,3;19,0,4;19,0,5|And the entire process of transferring technology to the marketplace could be harmed|Inh|Null|Null|Null||||2799..2811|19,0,1,1|that happens|Inh|Null|Null|Null|||||||||
Implicit|09|75||||2948|21||because|for example|Contingency.Cause.Reason||Expansion.Restatement.Specification||Wr|Comm|Null|Null||||2907..2946|20|The stakes in the controversy are large|Inh|Null|Null|Null||||2948..3150|21|Last year, venture capitalists spent an estimated $600 million to finance start-up companies in medical and biotechnology businesses, according to the National Venture Capital Association, a trade group|Ot|Comm|Null|Null|3082..3150|21,3,3;21,3,4;21,4|according to the National Venture Capital Association, a trade group||||||
Implicit|09|75||||3152|22||also||Expansion.Conjunction||||Ot|Comm|Null|Null|3082..3150|21,3,3;21,3,4;21,4|according to the National Venture Capital Association, a trade group|2948..3150|21|Last year, venture capitalists spent an estimated $600 million to finance start-up companies in medical and biotechnology businesses, according to the National Venture Capital Association, a trade group|Inh|Null|Null|Null||||3152..3317|22|Many of the deals involved transactions in which scientific institutions or researchers agreed to commercialize their work in return for an equity stake or royalties|Inh|Null|Null|Null|||||||||
Implicit|09|75||||3445|24||consequently||Contingency.Cause.Result||||Ot|Comm|Null|Null|3555..3562|24,1;24,2;24,3;24,4;24,5|he adds|3321..3386|23,0|In many of these deals, "venture capitalists had the inside track|Ot|Comm|Null|Null|3389..3443|23,1;23,2;23,3;23,4;23,5|says Lawrence Bock of Avalon Ventures, La Jolla, Calif|3445..3552|24,0|Investors were willing to gamble on new technologies because "we had exclusive rights to those technologies|Inh|Null|Null|Null|||||||||
Explicit|09|75|3498..3505|24,0,1,1,1,1,1,2,0|because|||because|||Contingency.Cause.Reason||||Ot|Comm|Null|Null|3555..3562|24,1;24,2;24,3;24,4;24,5|he adds|3445..3497|24,0,0;24,0,1,0;24,0,1,1,0;24,0,1,1,1,0;24,0,1,1,1,1,0;24,0,1,1,1,1,1,0;24,0,1,1,1,1,1,1|Investors were willing to gamble on new technologies|Inh|Null|Null|Null||||3507..3552|24,0,1,1,1,1,1,2,2|we had exclusive rights to those technologies|Inh|Null|Null|Null|||||||||
Explicit|09|75|3566..3569|25,0|But|||but|||Comparison.Contrast.Opposition||||Wr|Comm|Null|Null||||3321..3386|23,0|In many of these deals, "venture capitalists had the inside track|Ot|Comm|Null|Null|3389..3443|23,1;23,2;23,3;23,4;23,5|says Lawrence Bock of Avalon Ventures, La Jolla, Calif|3570..3706|25,1;25,2;25,3;25,4;25,5|under the proposed guidelines, all federally funded research will have to be reported publicly so that anyone can capitalize on the work|Inh|Null|Null|Null|||||||||
Explicit|09|75|3665..3672|25,4,1,1,1,1,1,3,0;25,4,1,1,1,1,1,3,1|so that|||so that|||Contingency.Cause.Result||||Wr|Comm|Null|Null||||3566..3664|25,0;25,1;25,2;25,3;25,4,0;25,4,1,0;25,4,1,1,0;25,4,1,1,1,0;25,4,1,1,1,1,0;25,4,1,1,1,1,1,0;25,4,1,1,1,1,1,1;25,4,1,1,1,1,1,2;25,5|But under the proposed guidelines, all federally funded research will have to be reported publicly|Inh|Null|Null|Null||||3673..3706|25,4,1,1,1,1,1,3,2|anyone can capitalize on the work|Inh|Null|Null|Null|||||||||
Implicit|09|75||||3709|26||as a result||Contingency.Cause.Result||||Wr|Comm|Null|Null||||3566..3706|25|But under the proposed guidelines, all federally funded research will have to be reported publicly so that anyone can capitalize on the work|Inh|Null|Null|Null||||3709..3807|26,1|Without the exclusivity, most venture capitalists won't have the incentive to invest in such deals|Ot|Comm|Null|Null|3810..3823|26,0;26,2;26,3;26,4;26,5;26,6|Mr. Bock says||||||
Explicit|09|75|3838..3849|27,2|for example|||for example|||Expansion.Instantiation||||Wr|Comm|Null|Null||||3566..3706|25|But under the proposed guidelines, all federally funded research will have to be reported publicly so that anyone can capitalize on the work|Inh|Null|Null|Null||||3827..3836;3851..4017|27,0;27,1;27,3;27,4;27,5;27,6|Last year Avalon and others invested $14 million in Athena Neurosciences Inc., South San Francisco, Calif., to license and develop technology for delivery of drugs to the brain|Inh|Null|Null|Null|||||||||
Explicit|09|75|4019..4022|28,0,0|But|||but|||Comparison||||Ot|Comm|Null|Null|4221..4234|28,1;28,2;28,3;28,4;28,5|Mr. Bock says|3827..4017|27|Last year, for example, Avalon and others invested $14 million in Athena Neurosciences Inc., South San Francisco, Calif., to license and develop technology for delivery of drugs to the brain|Inh|Null|Null|Null||||4023..4218|28,0,1;28,0,2;28,0,3;28,0,4|before Athena was able to get an exclusive license to the technology, the Federal Register published most of the details, "giving all of the company's potential competitors a chance to exploit it|Inh|Null|Null|Null|||||||||
Explicit|09|75|4023..4029|28,0,1,0|before|||before|||Temporal.Asynchronous.Precedence||||Ot|Comm|Null|Null|4221..4234|28,1;28,2;28,3;28,4;28,5|Mr. Bock says|4019..4022;4093..4218|28,0,0;28,0,2;28,0,3;28,0,4|But the Federal Register published most of the details, "giving all of the company's potential competitors a chance to exploit it|Inh|Null|Null|Null||||4030..4091|28,0,1,1|Athena was able to get an exclusive license to the technology|Inh|Null|Null|Null|||||||||
Implicit|09|75||||4236|29||although||Comparison||||Wr|Comm|Null|Null||||4019..4218|28,0|But before Athena was able to get an exclusive license to the technology, the Federal Register published most of the details, "giving all of the company's potential competitors a chance to exploit it|Ot|Comm|Null|Null|4221..4234|28,1;28,2;28,3;28,4;28,5|Mr. Bock says|4236..4297|29,0;29,1,0;29,2|Athena eventually acquired exclusive rights to the technology|Inh|Null|Null|Null|||||||||
Explicit|09|75|4330..4333|30,0|But|||but|||Comparison.Contrast||||Ot|Comm|Null|Null|4335..4348|30,1;30,2;30,3;30,4;30,5;30,7;30,8|says Mr. Bock|4236..4328|29|Athena eventually acquired exclusive rights to the technology and currently is developing it|Inh|Null|Null|Null||||4351..4370|30,6|It was a close call|Inh|Null|Null|Null|||||||||
Explicit|09|75|4405..4409|31,0,1,1|also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||3566..3706|25|But under the proposed guidelines, all federally funded research will have to be reported publicly so that anyone can capitalize on the work|Inh|Null|Null|Null||||4375..4404;4410..4486|31,0,0;31,0,1,0;31,0,1,2|The proposed guidelines could delay commercialization -- and force small companies to waste scarce capital|Ot|Comm|Null|Null|4488..4505|31,1;31,2;31,3;31,4|entrepreneurs say||||||
Implicit|09|75||||4507|32||because||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||4375..4486|31,0|The proposed guidelines could also delay commercialization -- and force small companies to waste scarce capital|Ot|Comm|Null|Null|4488..4505|31,1;31,2;31,3;31,4|entrepreneurs say|4507..4650|32,0|If start-ups can't have early access to research being conducted at institutions, "we have to replicate it ourselves or do without the research|Ot|Comm|Null|Null|4653..4765|32,1;32,2;32,3;32,4;32,5|says Ruth Emyanitoff, manager of business development at Applied bioTechnology Inc., a Cambridge, Mass., concern||||||
Explicit|09|75|4507..4509|32,0,0,0|If|||if|||Contingency.Condition.Hypothetical||||Ot|Comm|Null|Null|4653..4765|32,1;32,2;32,3;32,4;32,5|says Ruth Emyanitoff, manager of business development at Applied bioTechnology Inc., a Cambridge, Mass., concern|4590..4650|32,0,1;32,0,2;32,0,3;32,0,4|we have to replicate it ourselves or do without the research|Inh|Null|Null|Null||||4510..4587|32,0,0,1|start-ups can't have early access to research being conducted at institutions|Inh|Null|Null|Null|||||||||
Implicit|09|75||||4767|33||however||Comparison||||Wr|Comm|Null|Null||||4507..4650|32,0|If start-ups can't have early access to research being conducted at institutions, "we have to replicate it ourselves or do without the research|Ot|Comm|Null|Null|4653..4765|32,1;32,2;32,3;32,4;32,5|says Ruth Emyanitoff, manager of business development at Applied bioTechnology Inc., a Cambridge, Mass., concern|4767..4836|33,0|Duplicating research is both costly and time-consuming for a start-up|Ot|Comm|Null|Null|4838..4857|33,1;33,2;33,3;33,4|Ms. Emyanitoff says||||||
Implicit|09|75||||5018|35||because||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||4887..5015|34,3,1|that its guidelines "should not stifle research creativity or technology transfer from the research laboratory to commercial use|Ot|Comm|Null|Null|4861..4886|34,0;34,1;34,2;34,3,0;34,4;34,5|For its part, NIH insists|5018..5134|35,0|Universities such as Harvard and MIT should be able to develop a way to act as brokers for the individual scientists|Ot|Comm|Null|Null|5136..5155|35,1;35,2;35,3,0;35,3,1;35,4|says Katherine Bick||||||
Implicit|09|75||||5400|37||for example||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||5341..5398|36,1,1,1,1,1,1,1,1,1,1,1,1|that have already begun to surface in scientific ventures|Inh|Null|Null|Null||||5400..5533|37|Not long ago, scientists holding stock in Spectra Pharmaceutical Services Inc. were accused of falsifying research to boost the stock|Inh|Null|Null|Null|||||||||
Explicit|09|75|5554..5558|38,1,1|also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||5274..5398|36,1,1|the guidelines are essential to prevent the escalation of problems that have already begun to surface in scientific ventures|Ot|PAtt|Null|Null|5248..5273|36,0;36,1,0;36,2|NIH staff members believe|5535..5553;5559..5639|38,0;38,1,0;38,1,2;38,2|Many officials are concerned about companies getting a "free ride" on government-sponsored research|Inh|Null|Null|Null|||||||||
Implicit|09|75||||5641|39||in fact||Expansion.Conjunction|Contingency.Cause.Result|||Wr|Comm|Null|Null||||5535..5639|38|Many officials are also concerned about companies getting a "free ride" on government-sponsored research|Inh|Null|Null|Null||||5641..5781|39|A congressional subcommitee has been investigating the potential abuse from researchers holding stock in companies exploiting their research|Inh|Null|Null|Null|||||||||
Implicit|09|75||||6136|42||that is||Expansion.Restatement.Equivalence||||Wr|Comm|Null|Null||||6020..6133|41,1,1|the business and scientific community is overreacting to what the agency merely meant to be "ideas for discussion|Ot|Comm|Null|Null|5982..6019|41,0;41,1,0;41,2;41,3|Ms. Bick, the NIH administrator, says|6136..6174|42,0|The predictions of doom are "premature|Ot|Comm|Null|Null|6177..6185|42,1;42,2;42,3;42,4;42,5|she says||||||
Explicit|09|75|6189..6192|43,0,0|But|||but|||Comparison.Concession.Contra-expectation||||Wr|Comm|Null|Null||||6020..6133|41,1,1|the business and scientific community is overreacting to what the agency merely meant to be "ideas for discussion|Ot|Comm|Null|Null|5982..6019|41,0;41,1,0;41,2;41,3|Ms. Bick, the NIH administrator, says|6193..6281|43,0,1;43,0,2;43,0,3;43,0,4|when agencies like the NIH circulate guidelines, they've often already formulated policy|Ot|Comm|Null|Null|6283..6305|43,1;43,2;43,3;43,4|veteran scientists say||||||
Explicit|09|75|6193..6197|43,0,1,0|when|||when|||Contingency.Condition.General||||Ot|Comm|Null|Null|6283..6305|43,1;43,2;43,3;43,4|veteran scientists say|6189..6192;6242..6281|43,0,0;43,0,2;43,0,3;43,0,4|But they've often already formulated policy|Inh|Null|Null|Null||||6198..6240|43,0,1,1|agencies like the NIH circulate guidelines|Inh|Null|Null|Null|||||||||
Explicit|09|75|6307..6313|44,0|Indeed|||indeed|||Expansion.Conjunction|Contingency.Cause.Result|||Wr|Comm|Null|Null||||6189..6281|43,0|But when agencies like the NIH circulate guidelines, they've often already formulated policy|Ot|Comm|Null|Null|6283..6305|43,1;43,2;43,3;43,4|veteran scientists say|6315..6351|44,1;44,2;44,3;44,4;44,5|institutions already are taking note|Inh|Null|Null|Null|||||||||
Implicit|09|75||||6353|45||for example||Expansion.Instantiation||||Wr|Comm|Null|Null||||6307..6351|44|Indeed, institutions already are taking note|Inh|Null|Null|Null||||6353..6491|45|On Sept. 14, Harvard began circulating a conflict-of-interest policy statement that, in effect, would follow the NIH guidelines faithfully|Inh|Null|Null|Null|||||||||
Explicit|09|75|6544..6548|46,1,1|also|||also|||Expansion.List||||Wr|Comm|Null|Null||||6353..6491|45|On Sept. 14, Harvard began circulating a conflict-of-interest policy statement that, in effect, would follow the NIH guidelines faithfully|Inh|Null|Null|Null||||6495..6543;6549..6650|46,0;46,1,0;46,1,2;46,2|The University of California at San Francisco is circulating a memo among its scientific faculty that will restrict contact with the world of business|Inh|Null|Null|Null|||||||||
Implicit|09|75||||6652|47||and||Expansion.List||||Wr|Comm|Null|Null||||6495..6650|46|The University of California at San Francisco is also circulating a memo among its scientific faculty that will restrict contact with the world of business|Inh|Null|Null|Null||||6652..6767|47|In many other institutions, scientists are shunning contacts with venture investors until the NIH policy is settled|Inh|Null|Null|Null|||||||||
Explicit|09|75|6736..6741|47,3,1,2,0|until|||until|||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||6652..6735|47,0;47,1;47,2;47,3,0;47,3,1,0;47,3,1,1;47,4|In many other institutions, scientists are shunning contacts with venture investors|Inh|Null|Null|Null||||6742..6767|47,3,1,2,1|the NIH policy is settled|Inh|Null|Null|Null|||||||||
Implicit|09|75||||6872|49||because||Contingency.Cause.Reason||||Ot|Comm|Null|Null|6771..6808|48,0;48,1;48,2;48,3;48,5|Says Mr. Daly, the venture capitalist|6811..6870|48,4|It doesn't matter whether they call it guidelines or policy|Inh|Null|Null|Null||||6872..6898|49|The damage is already done|Inh|Null|Null|Null|||||||||
